Verona Pharma (I9SA) Stock Forecast & Price Target

Compare

― Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

I9SA Analyst Ratings

Currently, no data available

Based on NaN analysts giving stock ratings to

Verona

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

I9SA Stock 12 Month Forecast

There Are No Analyst Ratings for DE:I9SA In The Last 3 Months.

Highest Price Target―

Average Price Target―

Lowest Price Target―

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

I9SA Financial Forecast

I9SA Earnings Forecast

Next quarter’s earnings estimate for I9SA is $0.12 with a range of -$0.09 to $0.47. The previous quarter’s EPS was >-$0.01. I9SA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year I9SA has Preformed in-line its overall industry.

I9SA Sales Forecast

Next quarter’s sales forecast for I9SA is $99.25M with a range of $83.92M to $136.60M. The previous quarter’s sales results were $89.66M. I9SA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year I9SA has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts

Olivia Brayer

Cantor Fitzgerald

€86.03

Buy

―

Reiterated

10/07/25

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

Ram Selvaraju

H.C. Wainwright

€77.43→€92.05

Hold

―

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan Pachaiyappan

Roth MKM

€99.79→€92.05

Hold

―

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas Shrader

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon Lee

Truist Financial

€92.05

Hold

―

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen Rahimi

Piper Sandler

€137.65→€92.05

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Tiago Fauth

Wells Fargo

€92.05

Hold

―

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward Nash

Canaccord Genuity

€91.19→€92.05

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew Tsai

Jefferies

€120.44→€92.05

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara Bancroft

TD Cowen

€86.03→€92.05

Hold

―

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Olivia Brayer

Cantor Fitzgerald

€86.03

Buy

―

Reiterated

10/07/25

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

Ram Selvaraju

H.C. Wainwright

€77.43→€92.05

Hold

―

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan Pachaiyappan

Roth MKM

€99.79→€92.05

Hold

―

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas Shrader

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon Lee

Truist Financial

€92.05

Hold

―

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen Rahimi

Piper Sandler

€137.65→€92.05

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Tiago Fauth

Wells Fargo

€92.05

Hold

―

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward Nash

Canaccord Genuity

€91.19→€92.05

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew Tsai

Jefferies

€120.44→€92.05

Hold

―

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara Bancroft

TD Cowen

€86.03→€92.05

Hold

―

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verona Pharma

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+19.85%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +19.85% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+46.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.35% per trade.

1 Year

Olivia BrayerCantor Fitzgerald

Success Rate

2/2 ratings generated profit

Average Return

+48.10%

reiterated a buy rating last month

Copying Olivia Brayer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.10% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+48.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +48.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

I9SA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, I9SA has received 12 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. I9SA average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

I9SA Stock Forecast FAQ

What is DE:I9SA’s average 12-month price target, according to analysts?

Currently, no data Available

What is DE:I9SA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:I9SA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Verona Pharma a Buy, Sell or Hold?

Currently, no data Available

What is Verona Pharma’s share price target?

Currently, no data Available

What do analysts say about Verona Pharma?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of Verona Pharma?

To buy shares of DE:I9SA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Verona Pharma (I9SA) Stock Forecast & Price Target

I9SA Analyst Ratings

I9SA Stock 12 Month Forecast

I9SA Financial Forecast

I9SA Earnings Forecast

I9SA Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Verona Pharma

I9SA Analyst Recommendation Trends

I9SA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts